Patient Advocacy

The past decade has shown tremendous advances in the care of patients with lung cancer. With improved survival comes the opportunity for patients to become survivors who advocate for research by attending conferences, forming relationships with physicians and care providers, and lending their voices through committee involvement and speaking opportunities. The IASLC offers several opportunities to help transform patients into patient research advocates.

Spotlight

Neoadjuvant Chemotherapy-alone vs Chemoradiation followed by Sleeve Resection for Locally Advanced Non-Small Cell Lung Cancer

The important take-home from this study is that the addition of radiation therapy did not improve overall survival outcomes and more patients in that chemoradiation group had died 90 days after surgery.

IASLC Language Guide

The following Language Guide has been developed by members of the IASLC to provide guidelines on best practices with common phrases used during presentations at IASLC conferences and within submitted abstracts.

Download the Language Guide

Watch as Dr. Upal Basu Roy discusses survival data for patients with Stage III NSCLC from presentions from WCLC 2021.

Advocates at Work

Patient Advocate Lisa Briggs on Impact of Depression, Anxiety, and Distress in Patients During COVID-19

Read Patient Advocates discussion...Lisa Briggs on Effects of Depression, Anxiety, and Distress on Changes to Primary Treatment During COVID-19

As patients with lung cancer already present as a vulnerable population group with traditionally poorer survival outcomes, we do not have time to wait. Delays in care have devastating outcomes for both the individual and their loved ones and should be avoided where possible.

Read the Spotlight

Dr. D. Ross Camidge on Teliso-V Monotherapy in Patients With Previously Treated c-Met+ Advanced NSCLC

Watch as Dr. D. Ross Camidge discusses his presentations on Teliso-V Monotherapy in Patients With Previously Treated c-Met+ Advanced NSCLC presented at WCLC 2021.

Watch Now

John Hallick: Scientists and Clinicians are broadening their thinking beyond TKIs

Patients should know what to expect. Patients should also be aware of the typical side effects regarding amivantamab, the majority of which are related to the body’s reaction to the initial infusion.

Read the Spotlight

Phase I studies of DZD9008, an oral selective EGFR/HER2 inhibitor for patients with advanced NSCLC and EGFR Exon20 insertion mutations

I am hopeful that this drug will join the list of targeted agents that are extending the lives of heavily pretreated patients who have experienced disease progression...

Read the Spotlight

Mobocertinib for Patients with EGFR Exon 20 Insertion-Positive Metastatic NSCLC with Disease Progression on Prior EGFR TKI Therapy

We look forward to the U.S. Food and Drug Administration’s approval of this Breakthrough Therapy-designated EGFR tyrosine kinase inhibitor (TKI) in the coming months.

Read the Spotlight

Jill Feldman Discusses the IASLC Language Guide

Jill Feldman on the IASLC Language Guide

Watch as Jill Feldman discusses the new IASLC Language Guide. Ms. Feldman Highlights the importance of person-first language when writing and presenting on Lung Cancer data.

Watch Now

Ivy Elkins Discusses Real-World Treatment Patterns for Patients with EGFR-Positive Lung Cancer

Watch as Ivy Elkins, Co-Founder of the EGFR Resisters, comments her WCLC 2021 Presentation, Real-World Treatment Patterns for Patients with EGFR-Positive Lung Cancer

Listen as Ivy Elkins, Co-Founder of the EGFR Resisters, comments her WCLC 2021 Presentation, Real-World Treatment Patterns for Patients with EGFR-Positive Lung Cancer

Listen Now

Ivy Elkins on Pembroluzumab in Combination with Platinum-Based Chemo in Recurrent EGFR/ALK+ NSCLC

Ivy Elkins discusses Shirish M. Gadgeel's WCLC 2021 presentation Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Listen Now

Lung Cancer Disparities Are Indeed A Global Burden…and A Global Challenge

It is the responsibility of each one of us as part of the IASLC community to ensure that such cruel disparities in lung cancer care are overcome—otherwise, we will not be able to live peacefully with the burden of so many lives lost due to these inequalities.

Read the Spotlight

Jill Feldman on Improving Tobacco Cessation Among Individuals Undergoing Lung Cancer Screening

Watch as Patient Advocate Jill Feldman discusses April Plank's WCLC 2021 presentation "Improving Tobacco Cessation Among Individuals Undergoing Lung Cancer Screening."

Watch Now

Amy C. Moore, PhD discusses the EPICAL Trial

Amy C. Moore, PhD discusses the EPICAL Trial- a phase IB study combining anti-epidermal growth factor (EGF) vaccination with afatinib in EGFR-mutant non-small cell lung cancer.

Watch Now

Angus Pratt Discusses Medical Assistance in Dying (MAiD) in Lung Cancer

Angus Pratt on Medical Assistance in Dying in Patients with Lung Cancer

Watch as Angus Pratt Discusses Medical Assistance in Dying (MAiD) in Lung Cancer.

Watch Now

Advocacy Opportunities for IASLC Members

Cancer Care Team Award

Nominate your care team for outstanding provision of care.

Explore More

STARS

Learn how to read journal articles, understand clinical trial design, and communicate effectively with scientists and physicians regarding novel research. Apply to STARS today.

Learn More

Patient Advocate Committee

Apply for a position on the IASLC Patient Advocate Committee.

Apply Now

Pair Up With an IASLC Patient Advocate Partner

Contact us at [email protected] to be paired with an advocacy group based on your patient story.

Become a Member

Contact us about the complimentary membership for patients and advocates.

Apply Now

We proudly partner with 13+ advocacy organizations to advance the care of patients with lung cancer in patient-driven ways that focus on quality of care and quality of life.

Tools for Advocate Involvement

Journals

Learn about novel research and clinical care advances.

Learn more

Featured Meeting

Learn about novel research and clinical care advances.

Explore now

Share Your Story of Your Patient Research Advocate Journey

Learn about novel research and clinical care advances.

Share

Interested in Learning More with the IASLC for Advocacy Efforts/Program?

Interested in Learning More about the IASLC's Advocacy Programs? Contact us at [email protected] to meet our advocacy-focused staff, share your story, and learn more about advocacy opportunities

Contact Us Now!

Give Five!

The International Lung Cancer Foundation is excited about our newest donation functionality: recurring monthly donations! Donors now have the option to make their donations monthly recurring donations with just a few clicks of their mouse.

To help kick off our recurring donations program, we’re asking YOU to give five: $5 (or more!) each month for the next five months (or more!). If 5% of our members (approximately 400 people) gave five, we would raise USD 10,000 to inspire hope through research. Every dollar donated to the ILCF supports our Research Awards program, a global education initiative providing Fellowships and Young Investigator Awards that fund innovative research in lung cancer.

Give Five Today!